At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
In Brief
A Early Phase 1 clinical trial evaluating Nivolumab, Tadalafil, and 1 other intervention for Lip, Oral Cavity and Pharynx and Larynx. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
This randomized pilot early phase I trial studies how well nivolumab with or without tadalafil work in treating patients with head and neck squamous cell carcinoma that has come back and can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Tadalafil may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and tadalafil may work better in treating patients head and neck squamous cell carcinoma.
Study Details
Timeline
Interventions
Given IV
Given orally
Undergo surgery